Vimentin 3 Expression in Prostate Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Vimentin3 (Vim3) has been identified as a potential tumor marker for distinguishing between benign and malignant kidney tumors.
• The role and regulation of Vim3 expression in prostate cancer (PCa) remain largely unexplored.
• Endothelin receptors (ETRs) are implicated in various cancer processes, including cell proliferation and migration.

Purpose of the Study:

• To investigate the expression of Vimentin3 (Vim3) in prostate cancer (PCa) cell lines.
• To elucidate the regulatory role of endothelin receptors (ETRs) in Vim3 expression within PCa.
• To assess the potential of Vim3 as a diagnostic marker for prostate cancer.

Main Methods:

• Prostate cancer cell lines (PC3, DU145, LNCap) were treated with endothelin 1 (ET-1) and specific endothelin receptor antagonists (BQ123 for ETAR, BQ788 for ETBR).
• Cell migration was assessed using a scratch assay.
• Vim3 expression levels were quantified using western blotting and quantitative real-time PCR (qRT-PCR).

Main Results:

• Endothelin 1 (ET-1) treatment led to the overexpression of Vim3 in prostate cancer cell lines.
• Blocking the endothelin B receptor (ETBR) significantly increased cell migration rates.
• Vim3 expression was markedly elevated in cell lines where ETBR function was inhibited or absent.

Conclusions:

• Vim3 expression is upregulated in prostate cancer cells lacking functional endothelin B receptors (ETBRs).
• The findings suggest a potential link between Vim3 expression and ETBR status in prostate cancer.
• Vim3 may serve as a valuable tumor marker for identifying prostate cancers associated with ETBR methylation.